<p>Farmers Trust Co. 在第一季度增持吉利德科学公司（NASDAQ:GILD - 免费报告）的持股比例增加了 28.3％，根据该公司最近向美国证券交易委员会提交的 13F 申报文件。该基金在本季度购买了额外的 13,375 股股票后，持有这家生物制药公司的 60,705 股股票。Farmers Trust Co. 在最新报告期结束时持有的吉利德科学股票价值为 4,447,000 美元。</p>
<p>获取 <strong>吉利德科学</strong> 警报：</p>
<ul>
<li>生物技术行业接近突破：第二季度表现如何？</li>
</ul>
<p>其他几家对冲基金最近也增加或减少了他们在 GILD 的持股。Altfest L J &amp; Co. Inc. 在第四季度收购了价值 210,000 美元的吉利德科学股票。Federated Hermes Inc. 在第四季度增加了 4.9％的吉利德科学股票持仓。Federated Hermes Inc. 现在拥有 3,787,355 股这家生物制药公司的股票，价值 306,814,000 美元，比上一季度增加了 175,925 股。Charles Schwab Investment Management Inc. 在第四季度增加了 1.2％的吉利德科学股票持仓。Charles Schwab Investment Management Inc. 现在拥有 7,281,489 股这家生物制药公司的股票，价值 589,873,000 美元，比上一季度增加了 87,482 股。Wetzel Investment Advisors Inc. 在第四季度购入了价值约 74,000 美元的吉利德科学股票。最后，Eagle Asset Management Inc. 在第四季度增加了 23.6％的吉利德科学股票持仓。Eagle Asset Management Inc. 现在拥有 317,539 股这家生物制药公司的股票，价值 25,724,000 美元，比上一季度增加了 60,697 股。83.67％的股份由机构投资者和对冲基金持有。</p>
<h2>吉利德科学股价上涨 3.9%</h2>
<p>周四午盘时，纳斯达克 GILD 股价上涨 2.45 美元，达到 65.60 美元。公司股票交易量为 2,336,968 股，相比其平均交易量 7,222,083 股有所减少。该公司的市值为 817.3 亿美元，市盈率为 175.42，市盈增长比为 1.27，β值为 0.20。吉利德科学股票的 52 周最低价为 62.07 美元，最高价为 87.86 美元。公司的 50 天简单移动平均线为 65.69 美元，200 天简单移动平均线为 73.06 美元。公司的资产负债比为 1.31，流动比率为 1.08，速动比率为 0.94。</p>
<ul>
<li>基因疗法：为什么一次治疗要花费数百万美元？</li>
</ul>
<p>吉利德科学（NASDAQ:GILD - 获取免费报告）于 4 月 25 日星期四发布了其盈利结果。这家生物制药公司报告本季度每股收益（EPS）为（1.32）美元，超过分析师预期的（1.49）美元，超出 0.17 美元。该公司本季度营收为 66.9 亿美元，而分析师预期为 63.6 亿美元。吉利德科学的净资产回报率为 24.34％，净利润率为 1.76％。公司本季度的营收同比增长 5.3％。在去年同期的同一季度，公司每股盈利为 1.37 美元。研究分析师预测，吉利德科学公司本财年将实现 3.75 美元的每股收益。</p>
<h2>吉利德科学宣布股息</h2>
<p>该公司最近宣布了季度股息，将于 6 月 27 日星期四支付。6 月 14 日星期五持股的投资者将获得 0.77 美元的股息。该股息的除息日为 6 月 14 日星期五。这代表年化基础上的 3.08 美元股息和 4.70％的股息率。吉利德科学的股息支付比率（DPR）目前为 855.56％。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>分析师看好这两家中型生物技术公司的 50％以上增长</li>
</ul>
<p>GILD 最近受到多家分析师报告的关注。Maxim Group 将吉利德科学的价格目标从 90.00 美元下调至 85.00 美元，并为该公司设定了 “买入” 评级，报告发布于 5 月 1 日星期三。Oppenheimer 重申了对吉利德科学的 “表现优异” 评级，并设定了 105.00 美元的目标股价，报告发布于 4 月 19 日星期五。StockNews.com 将吉利德科学的评级从 “买入” 提升至 “强烈买入”，报告发布于 4 月 27 日星期六。TD Cowen 将吉利德科学的目标股价从 90.00 美元下调至 85.00 美元，并为该公司设定了 “买入” 评级，报告发布于 4 月 26 日星期五。最后，富国银行将吉利德科学的目标股价从 84.00 美元下调至 77.00 美元，并为该公司设定了 “中性” 评级，报告发布于 3 月 4 日星期一。十一家分析师对该股票给予持有评级，六家给予买入评级，一家给予强烈买入评级。根据 MarketBeat，该股票的平均评级为 “持有”，目标股价的共识为 83.69 美元。</p>
<p><strong>查看我们对 GILD 的最新研究报告</strong></p>
<h2>吉利德科学内部交易活动</h2>
<p>在其他吉利德科学的消息中，内部人员 Merdad Parsey 于 4 月 1 日星期一以每股 72.96 美元的平均价格出售了 2,000 股公司股票。该内部人员在交易后直接持有公司 96,304 股股票，价值 7,026,339.84 美元。该交易已在提交给美国证券交易委员会的文件中披露，可通过 SEC 网站访问。公司内部人员持有公司股份的比例为 0.16％。</p>
<h2>吉利德科学公司简介（免费报告）</h2>
<p>吉利德科学公司是一家生物制药公司，致力于在美国、欧洲和国际市场上发现、开发和销售满足医疗需求的药物。该公司提供 Biktarvy、Genvoya、Descovy、Odefsey、Truvada、Complera/ Eviplera、Stribild、Sunlencs 和 Atripla 等产品，用于治疗 HIV/AIDS；Veklury，一种用于静脉注射的注射剂，用于治疗 COVID-19；以及 Epclusa、Harvoni、Vemlidy 和 Viread，用于治疗病毒性肝炎。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们比吉利德科学更喜欢的股票</li>
<li>什么是股息王？</li>
<li>3 家科技股公司内部人员、主要股东和机构正在购买</li>
<li>最具波动性的股票，投资者需要了解的事项</li>
<li>能源板块进入买入区域，现在应该买入的前 3 只股票</li>
<li>什么是低市盈率，对投资者意味着什么？</li>
<li>Autodesk 股价上涨 25%，分析师希望获得更多两位数增长</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 从埃隆·马斯克的$16T 加密情节（来自 Crypto 101 Media）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mjgz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mjgz"/></p>
<h2>现在是否值得投资$1,000 美元购买吉利德科学？</h2>
<p>在考虑吉利德科学之前，您需要听到这个。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票清单...而吉利德科学不在名单上。</p>
<p>尽管吉利德科学目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

吉利德科学

<p>农民信托公司根据其向美国证券交易委员会提交的 13F 文件，在第一季度增加了对吉利德科学的持股比例，增幅为 28.3%。该公司现在拥有 60,705 股，价值 4,447,000 美元。其他对冲基金也增加了他们在吉利德科学的持股。吉利德科学最近宣布了季度股息，分析师预测其股价将增长超过 50%</p>

<p>Farmers Trust Co. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 28.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 60,705 shares of the biopharmaceutical company's stock after purchasing an additional 13,375 shares during the quarter. Farmers Trust Co.'s holdings in Gilead Sciences were worth $4,447,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Farmers Trust Co. 在第一季度增持吉利德科学公司（NASDAQ:GILD - 免费报告）的持股比例增加了 28.3％，根据该公司最近向美国证券交易委员会提交的 13F 申报文件。该基金在本季度购买了额外的 13,375 股股票后，持有这家生物制药公司的 60,705 股股票。Farmers Trust Co. 在最新报告期结束时持有的吉利德科学股票价值为 4,447,000 美元。</p>
</div><p>Get <strong>Gilead Sciences</strong> alerts:</p>
<ul>
<li>Biotech Sector Nears Breakout: Will it Outperform in Q2?</li>
</ul>
<div class="lb-trans"><p>获取 <strong>吉利德科学</strong> 警报：</p>
<ul>
<li>生物技术行业接近突破：第二季度表现如何？</li>
</ul>
</div><p>Several other hedge funds have also recently added to or reduced their stakes in GILD. Altfest L J &amp; Co. Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter worth $210,000. Federated Hermes Inc. increased its position in shares of Gilead Sciences by 4.9% during the 4th quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company's stock worth $306,814,000 after purchasing an additional 175,925 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Gilead Sciences by 1.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company's stock worth $589,873,000 after purchasing an additional 87,482 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new stake in shares of Gilead Sciences during the 4th quarter worth about $74,000. Finally, Eagle Asset Management Inc. increased its position in shares of Gilead Sciences by 23.6% during the 4th quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company's stock worth $25,724,000 after purchasing an additional 60,697 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也增加或减少了他们在 GILD 的持股。Altfest L J &amp; Co. Inc. 在第四季度收购了价值 210,000 美元的吉利德科学股票。Federated Hermes Inc. 在第四季度增加了 4.9％的吉利德科学股票持仓。Federated Hermes Inc. 现在拥有 3,787,355 股这家生物制药公司的股票，价值 306,814,000 美元，比上一季度增加了 175,925 股。Charles Schwab Investment Management Inc. 在第四季度增加了 1.2％的吉利德科学股票持仓。Charles Schwab Investment Management Inc. 现在拥有 7,281,489 股这家生物制药公司的股票，价值 589,873,000 美元，比上一季度增加了 87,482 股。Wetzel Investment Advisors Inc. 在第四季度购入了价值约 74,000 美元的吉利德科学股票。最后，Eagle Asset Management Inc. 在第四季度增加了 23.6％的吉利德科学股票持仓。Eagle Asset Management Inc. 现在拥有 317,539 股这家生物制药公司的股票，价值 25,724,000 美元，比上一季度增加了 60,697 股。83.67％的股份由机构投资者和对冲基金持有。</p>
</div><h2>Gilead Sciences Stock Up 3.9 %</h2>
<div class="lb-trans"><h2>吉利德科学股价上涨 3.9%</h2>
</div><p>Shares of NASDAQ GILD traded up $2.45 during midday trading on Thursday, hitting $65.60. 2,336,968 shares of the company's stock were exchanged, compared to its average volume of 7,222,083. The company has a market cap of $81.73 billion, a PE ratio of 175.42, a P/E/G ratio of 1.27 and a beta of 0.20. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The firm's fifty day simple moving average is $65.69 and its 200-day simple moving average is $73.06. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94.</p>
<ul>
<li>Gene therapy: Why does it cost millions for a single treatment?</li>
</ul>
<div class="lb-trans"><p>周四午盘时，纳斯达克 GILD 股价上涨 2.45 美元，达到 65.60 美元。公司股票交易量为 2,336,968 股，相比其平均交易量 7,222,083 股有所减少。该公司的市值为 817.3 亿美元，市盈率为 175.42，市盈增长比为 1.27，β值为 0.20。吉利德科学股票的 52 周最低价为 62.07 美元，最高价为 87.86 美元。公司的 50 天简单移动平均线为 65.69 美元，200 天简单移动平均线为 73.06 美元。公司的资产负债比为 1.31，流动比率为 1.08，速动比率为 0.94。</p>
<ul>
<li>基因疗法：为什么一次治疗要花费数百万美元？</li>
</ul>
</div><p>Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.37 earnings per share. Research analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>吉利德科学（NASDAQ:GILD - 获取免费报告）于 4 月 25 日星期四发布了其盈利结果。这家生物制药公司报告本季度每股收益（EPS）为（1.32）美元，超过分析师预期的（1.49）美元，超出 0.17 美元。该公司本季度营收为 66.9 亿美元，而分析师预期为 63.6 亿美元。吉利德科学的净资产回报率为 24.34％，净利润率为 1.76％。公司本季度的营收同比增长 5.3％。在去年同期的同一季度，公司每股盈利为 1.37 美元。研究分析师预测，吉利德科学公司本财年将实现 3.75 美元的每股收益。</p>
</div><h2>Gilead Sciences Announces Dividend</h2>
<div class="lb-trans"><h2>吉利德科学宣布股息</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.70%. Gilead Sciences's dividend payout ratio (DPR) is presently 855.56%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，将于 6 月 27 日星期四支付。6 月 14 日星期五持股的投资者将获得 0.77 美元的股息。该股息的除息日为 6 月 14 日星期五。这代表年化基础上的 3.08 美元股息和 4.70％的股息率。吉利德科学的股息支付比率（DPR）目前为 855.56％。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<ul>
<li>Analysts see over 50% gains in these 2 mid-cap biotech stocks</li>
</ul>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
<ul>
<li>分析师看好这两家中型生物技术公司的 50％以上增长</li>
</ul>
</div><p>GILD has been the subject of a number of recent analyst reports. Maxim Group cut their price objective on Gilead Sciences from $90.00 to $85.00 and set a &#34;buy&#34; rating for the company in a research report on Wednesday, May 1st. Oppenheimer restated an &#34;outperform&#34; rating and set a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. StockNews.com upgraded Gilead Sciences from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, April 27th. TD Cowen lowered their target price on Gilead Sciences from $90.00 to $85.00 and set a &#34;buy&#34; rating for the company in a report on Friday, April 26th. Finally, Wells Fargo &amp; Company lowered their target price on Gilead Sciences from $84.00 to $77.00 and set an &#34;equal weight&#34; rating for the company in a report on Monday, March 4th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of &#34;Hold&#34; and a consensus target price of $83.69.</p>
<div class="lb-trans"><p>GILD 最近受到多家分析师报告的关注。Maxim Group 将吉利德科学的价格目标从 90.00 美元下调至 85.00 美元，并为该公司设定了 “买入” 评级，报告发布于 5 月 1 日星期三。Oppenheimer 重申了对吉利德科学的 “表现优异” 评级，并设定了 105.00 美元的目标股价，报告发布于 4 月 19 日星期五。StockNews.com 将吉利德科学的评级从 “买入” 提升至 “强烈买入”，报告发布于 4 月 27 日星期六。TD Cowen 将吉利德科学的目标股价从 90.00 美元下调至 85.00 美元，并为该公司设定了 “买入” 评级，报告发布于 4 月 26 日星期五。最后，富国银行将吉利德科学的目标股价从 84.00 美元下调至 77.00 美元，并为该公司设定了 “中性” 评级，报告发布于 3 月 4 日星期一。十一家分析师对该股票给予持有评级，六家给予买入评级，一家给予强烈买入评级。根据 MarketBeat，该股票的平均评级为 “持有”，目标股价的共识为 83.69 美元。</p>
</div><p><strong>View Our Latest Research Report on GILD</strong></p>
<div class="lb-trans"><p><strong>查看我们对 GILD 的最新研究报告</strong></p>
</div><h2>Insider Activity at Gilead Sciences</h2>
<div class="lb-trans"><h2>吉利德科学内部交易活动</h2>
</div><p>In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company's stock.</p>
<div class="lb-trans"><p>在其他吉利德科学的消息中，内部人员 Merdad Parsey 于 4 月 1 日星期一以每股 72.96 美元的平均价格出售了 2,000 股公司股票。该内部人员在交易后直接持有公司 96,304 股股票，价值 7,026,339.84 美元。该交易已在提交给美国证券交易委员会的文件中披露，可通过 SEC 网站访问。公司内部人员持有公司股份的比例为 0.16％。</p>
</div><h2>Gilead Sciences Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>吉利德科学公司简介（免费报告）</h2>
</div><p>Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.</p>
<div class="lb-trans"><p>吉利德科学公司是一家生物制药公司，致力于在美国、欧洲和国际市场上发现、开发和销售满足医疗需求的药物。该公司提供 Biktarvy、Genvoya、Descovy、Odefsey、Truvada、Complera/ Eviplera、Stribild、Sunlencs 和 Atripla 等产品，用于治疗 HIV/AIDS；Veklury，一种用于静脉注射的注射剂，用于治疗 COVID-19；以及 Epclusa、Harvoni、Vemlidy 和 Viread，用于治疗病毒性肝炎。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Gilead Sciences</li>
<li>What is a Dividend King?</li>
<li>3 Tech Stocks Insiders, Major Shareholders, and Institutions Buy</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>Top 3 Stocks to Buy Now as Energy Sector Hits Buy Zone</li>
<li>What is a Low P/E Ratio and What Does it Tell Investors?</li>
<li>Autodesk Stock Up 25%, Analysts Want More Double-Digit Gains</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>五只我们比吉利德科学更喜欢的股票</li>
<li>什么是股息王？</li>
<li>3 家科技股公司内部人员、主要股东和机构正在购买</li>
<li>最具波动性的股票，投资者需要了解的事项</li>
<li>能源板块进入买入区域，现在应该买入的前 3 只股票</li>
<li>什么是低市盈率，对投资者意味着什么？</li>
<li>Autodesk 股价上涨 25%，分析师希望获得更多两位数增长</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=GILD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ $16T Crypto Plot From Elon Musk (From Crypto 101 Media)(Ad)</p>
<div class="lb-trans"><p>→ 从埃隆·马斯克的$16T 加密情节（来自 Crypto 101 Media）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mjgz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8283&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Gilead Sciences right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 美元购买吉利德科学？</h2>
</div><p>Before you consider Gilead Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑吉利德科学之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票清单...而吉利德科学不在名单上。</p>
</div><p>While Gilead Sciences currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管吉利德科学目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

吉利德科学公司（NASDAQ:GILD）的股份被 Farmers Trust Co.购买